Also known as: anito-cel
Anitocabtagene autoleucel (anito-cel) is an investigational BCMA-directed CAR T-cell therapy for multiple myeloma developed by Kite and Arcellx. It has shown deep and durable responses in clinical studies and has entered late-stage regulatory review in the U.S. for relapsed/refractory disease. The program remains pre-approval pending FDA action.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Gilead Sciences will acquire Arcellx for $7.8 billion to expand their CAR-T cell therapy collaboration. The deal includes $115 per share at closing plus contingent payments based on sales milestones.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Gilead Sciences entered a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 contingent value right, representing an implied equity value of $7.8 billion. The acquisition provides Gilead with full control of anito-cel, an investigational BCMA-directed CAR T-cell therapy for multiple myeloma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07045909 |
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) |
RECRUITING | PHASE2 |
| NCT06413498 |
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma |
RECRUITING | PHASE3 |
